Pursuant to Regulation 30 read with Schedule III of the SEBI (LODR) Regulations, 2015, we wish to inform you that Board of Directors in its meeting held today i.e. on Tuesday, 2nd September, ....
Awaiting price reaction for this filing.
The Board of Directors of MPS Pharmaa Limited met on September 2, 2025, and approved key items including fixing September 29, 2025, as the date for the 31st Annual General Meeting (AGM). The Board also approved the Notice for the 31st AGM along with the Director's Report and Management Discussion & Analysis Report for FY 2024-25. Book closure was fixed from September 23 to September 29, 2025, and e-voting will be conducted via NSDL from September 26 to September 28, 2025, with September 22, 2025 as the cut-off date. Notably, the Board approved a strategic diversification into the manufacturing of Ayurvedic, Unani, Homeopathic medicines, and Nutraceuticals. Additionally, M/s. Kundan Agrawal & Co. was recommended as Secretarial Auditor for a five-year term (FY 2025-26 to FY 2029-30), and renowned Ayurvedacharya Mr. Kamal Joshi was appointed as Senior Consultant to drive the new venture.
The diversification into Ayurvedic and alternative medicine manufacturing marks a significant strategic shift for the company, potentially opening new revenue streams aligned with growing demand for natural healthcare. The appointment of an experienced Ayurvedacharya signals serious intent behind the diversification, which could be viewed positively by investors, though execution risks remain for a company entering a new segment.